Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12789MR)

This product GTTS-WQ12789MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12789MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5385MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ9535MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ6268MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ10375MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ1563MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ12881MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ8311MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ4270MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW